Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

If your physician prescribes a new branded drug, though, you and your insurance company have few options. Patent-protected exclusivity is the reason pharmaceutical stocks are known for delivering ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Pfizer yields 5.57% with a B- dividend safety rating, known for Eliquis and Xeljanz. Find out why I'm bullish on PFE stock.

Starboard Value engages with Pfizer's leadership amid growing concerns over the company's trajectory. Meanwhile, Pfizer reports a significant survival benefit in prostate cancer patients from its ...